Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Interferon Alfa-2a in CML, MM, and RCC
NCT02829775Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2004
- Primary completion
- Jan 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 7
01
Overview
A Phase 3 trial of peginterferon alfa-2a, interferon alfa-2a in chronic myelogenous leukemia (CML), Malignant Melanoma (MM), renal cell carcinoma (RCC), sponsored by Roche. Started Jan 2004; status: completed.
02
Drugs
peginterferon alfa-2ainterferon alfa-2a
03
Conditions
chronic myelogenous leukemia (CML)Malignant Melanoma (MM)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02829775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829775.